Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMP-9 inhibitor (RNAi)
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MMP-9 inhibitor (RNAi) refers to RNA interference-based therapeutic agents, such as small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs), designed to selectively knock down the expression of matrix metalloproteinase-9 (MMP-9). MMP-9 is a zinc-dependent endopeptidase involved in extracellular matrix degradation, tissue remodeling, and inflammatory processes. In the context of chronic hepatitis B virus (HBV) infection, MMP-9 has been shown to negatively regulate anti-HBV B-cell responses and suppress interferon-mediated antiviral pathways. Knockdown of MMP-9 via RNAi has demonstrated preclinical efficacy in accelerating the clearance of hepatitis B surface antigen (HBsAg) and enhancing hepatitis B surface antibody (HBsAb) production, suggesting its potential as a novel therapeutic strategy for chronic HBV.
- Other names
- MMP-9 RNAiMMP9 RNAiMMP 9 RNAiMMP-9 shRNAMMP9 shRNAMMP 9 shRNAMMP-9 siRNAMMP9 siRNAMMP 9 siRNAmatrix metalloproteinase-9 RNAimatrix metalloproteinase-9 shRNAmatrix metalloproteinase-9 siRNA
02
Targets
MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on MMP-9 inhibitor (RNAi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMP-9 inhibitor (RNAi).